A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) led by Dr. Andrés Hidalgo has discovered a specialized population of neutrophils in the skin that produce extracellular matrix, ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into ...

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

Boehringer Ingelheim and Veeva (VEEV) Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing ...

Together, the three molecules have been shared with more than 100 laboratories in 22 countries via Boehringer’s open innovation portal opnMe.com in 2024. “By making these molecules easily accessible ...

ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...